Although the causative agent of the acquired immune deficiency syndrome has been identified to be the human immunodeficiency virus type 1 (HIV-1) (1, 4, 13) , the mechanism of immune deficiency has not been fully elucidated. Specific immune responses such as neutralizing antibody, cytotoxic T lymphocytes, T-cell responses, antibody-dependent cell-mediated cytotoxicity, and natural killer cell responses against HIV-1 have been described, but their roles in immunopathogenesis have yet to be determined. Several recent reports have described an immunological phenomenon called antibody-dependent enhancement (ADE) of HIV-1 infection (8, 10, 23, 24, 31) . Two in vitro mechanisms for ADE have been evaluated. The first involves the alternative pathway of complement and antibody to the envelope glycoprotein of HIV-1 (24, 25) ; the second requires antibody to HIV-1 and cells bearing Fc receptors (8, 10, 31) . Complement-mediated ADE (C'-ADE) has been determined to require both CD4 receptors and complement receptor type 2 (21, 26) . This complement-dependent mechanism has been called complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-1 infection, while the latter complement-independent mechanism has been called Fc receptormediated, antibody-dependent enhancement (FcR-ADE) of HIV-1 infection (8, 10, 31) .
Although no antigenic regions have been described for FcR-ADE, a significant body of evidence suggests that the envelope glycoproteins of HIV-1 are important in C'-ADE of HIV-1 infection. Previous reports have shown that antibodies conferring C'-ADE were bound and eluted from a pENV9 column (25) . The pENV9 polypeptide is a nonglycosylated recombinant fragment of the C-terminal 20 amino * Corresponding author.
acids of gpl20 and the amino-terminal half of gp4l produced in Escherichia coli (18) . Three human monoclonal antibodies (huMAbs) against HIV-1 that enhanced HIV-1 infection in vitro via a complement-mediated mechanism were shown to bind to the pENV9 fragment of HIV-1 (20) . Two of those huMAbs have been shown to compete for a similar epitope on HIV-1. Those two huMAbs were evaluated further in this study by mapping their binding specificities to a 35-aminoacid immunodominant region of gp4l and demonstrating that this peptide blocked C'-ADE mediated by the two huMAbs and by human polyclonal anti-HIV-1 serum.
MATERIALS AND METHODS Cells and virus. A clone of the human T-lymphotropic virus type 1-transformed T-lymphoblastoid cell line MT-2, expressing high levels of both CD4 and complement receptor type 2 (21), was generously donated by D. D. Richman (San Diego, Calif.). H9 cells chronically infected with the HTLV-"'B isolate of HIV-1 (HIV3B) were obtained from R. C.
Gallo's laboratory (National Institutes of Health, Bethesda, Md.). All cell lines were maintained in RPMI-1640 supplemented with 12% fetal calf serum and containing 50 ,ug of gentamicin per ml (growth medium). Virus was obtained from culture supernatants clarified of cells by low-speed centrifugation followed by filtration (0.45-,um pore size).
Peptides. Peptides 140, 110, and 120 were purchased from IAF Biochem (Natick, Mass.). Peptides were confirmed to be 99% pure by reverse-phase high-pressure liquid chromatography and amino acid analysis. The irrelevant HIV-1 gp4l peptide p-peptide was a gift from T. Palker (Duke University, Durham, N.C.).
HuMAbs. The huMAbs were obtained by fusion of lymphocytes from an HIV-1 antibody-positive individual with P3x36 AgUl cells and have been described previously (30 p,g/ml) or HIVIG (1:500 dilution) and 1:20-diluted human complement. Next, HIV-1 was added and incubated at 37°C for 1 h, then 2 x 105 MT-2 cells were added to each well, and cells were incubated for 2.5 days at 37°C in sealed modular incubators containing 5% C02-95% air. Cells were harvested for cytopathic effect as described before (15), and viable cells were quantitated with Finter neutral red dye. The A540 was measured with a Flow Titer Tek II microcolorimeter. Controls were HIV-1 and complement plus MT-2 cells (100% viable) and HIV-1, antibody, complement, and MT-2 cells (0% viable).
RT release and antigen synthesis. First, in triplicate wells of a 24-well plate, huMAb 86 was diluted 1:50 (20 ,ug/ml) in growth medium containing human complement (1:20 dilution) and peptide 140 (20 ,ug/ml) or an irrelevant HIV-1 peptide (20 p,g/ml). After 30 min at 37°C, HIV-1 was added and incubated for 1 h at 37°C. Finally, 1 ml of MT-2 cell suspension was added, and cells were incubated for 12 h at 37°C. Virus and antibody were then removed. Cells were incubated in 2 ml of fresh growth medium at 37°C for 60 h. Cultures were harvested for reverse transcriptase (RT) release by the method of Poiesz et al. (16) , and HIV-1 antigen-positive cells were quantitated by immunofluorescence (IF) as described before (22) . None of the peptides were growth inhibitory at 20 p,g/ml. (20) . The antigen specificities of these two huMAbs were previously shown to be against HIV-1 envelope glycoproteins (20 ) . In other experiments, three other huMAbs, U7-2 (anti-gag) and N2-4 and 13 (both anti-env), were tested at 300 ng/ml (Table 1) . At these higher antibody concentrations (300 ng/ml), positive OD values were greater than 0.25. Both of the nonenhancing anti-env huMAbs, 13 and N2-4, and the anti-gag antibody, U7-2, were negative for binding to peptide 140. The sequences of the three peptides and their relationship to the HIV-1 envelope glycoprotein are illustrated in Fig. 1 .
Peptide 140 blocks C'-ADE in vitro. To determine whether peptides 110, 120, and 140 had any biological effect, enhancing assays in the presence of each of the three peptides were performed as described before (21, 24, 27) with huMAb 86 ( Fig. 2A) and an HIV-1 antibody-positive gamma globulin fraction (HIVIG) (Fig. 2B ). The HIVIG was tested at dilutions of 1:500 (Fig. 2B ) and 1:1,000 (not shown). These concentrations are subneutralizing in the presence of complement, as demonstrated previously (27) . As shown in Peptide 120
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Peptide 110 2A, only peptide 140 blocked C'-ADE by huMAb 86. Complete blockade of C'-ADE is indicated by 100% cell viability. Therefore, peptide 140 blocked C'-ADE at concentrations greater than 1 xLg/ml, while neither peptide 110 nor peptide 120 had any effect. Peptide 140 also blocked C'-ADE mediated by polyclonal HIV-1 antibody-positive serum. In this experiment, 100% viability indicates complete (100%) protection from C'-ADE. No protection from C'-ADE is indicated by 0% viability. As shown in Fig. 2B , peptide 140 gave >50% protection at concentrations greater than 1 ,ug/ml, while neither peptide 120 nor peptide 110 gave greater than 30% protection from C'-ADE. Therefore, one domain to which antibodies that cause C'-ADE of HIV-1 infection bind is encoded by the peptide 140. This peptide corresponds to amino acids 586 to 620 of HIV3B (19) . This peptide has been demonstrated to be an immunodominant portion of gp4l (3, 5, 11, 28, 29) and lies within the pENV9 polypeptide (18) . Because this peptide significantly blocked C'-ADE mediated by HIVIG, it seems likely that this peptide binds a significant portion of the enhancing antibodies present in HIV-1 antibody-positive serum. Furthermore, it is likely that only a small number of enhancing domains exist, since one peptide significantly reduced C'-ADE of HIV-1 infection. Efforts to map the actual epitopes to which V10-9 and 86 bind are under way.
Blockade of C'-ADE confirmed by RT release and antigen synthesis. a Percent IF-positive cells was determined by using HIV-1 antibodypositive serum and a 1:200 dilution of anti-human IgG as described before (22) .
b RT release in 0.75-ml samples was assayed by incorporation of 3H-dTTP into a poly(rA)-oligo(dT) template, using the method of Poiesz et al. (16) . (Table 1 ), the huMAbs were tested at multiple concentrations from 3 ,ug/ml to 1 ng/ml. Only huMAbs 86 and V10-9 bound to peptide 140 and only at concentrations greater than 3 ng/ml. These two huMAbs did not react with other peptides. In addition, these two (14) .
The results reported here demonstrate that one domain of the gp4l molecule, amino acids 586 to 620, contains an epitope(s) that induces the production in vivo of antibodies that enhance HIV-1 infection in vitro. Since such a region is immunodominant (3, 5, 11, 28, 29) and has no neutralizing activity, it may be of benefit to delete such a region from candidate anti-HIV-1 vaccines. The identification of huMAbs that enhance HIV-1 infection in vitro and domains of the HIV-1 gp4l that induce the production of such enhancing antibodies offers a major first step in the search for in vivo relevance of C'-ADE of HIV-1 infection and could improve the ability to formulate a successful anti-HIV vaccine.
